A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
Hai-Yan TuJifeng FengMeiqi ShiJun ZhaoYuyan WangJianhua ChangJialei WangYing ChengJing ZhuEng-Huat TanKai LiYiping ZhangVictor LeeCheng-Ta YangWu-Chou SuDavid Chi-Leung LamB J SrinivasaSenthil RajappaChing-Liang HoKwok Chi LamYi HuShailesh Arjun BondardeXiaoqing LiuYahui TianZhiyi XueAgnieszka CsehDennis Chin-Lun HuangCaicun ZhouYi-Long WuPublished in: Targeted oncology (2022)
NCT01953913 (1 October 2013).
Keyphrases
- small cell lung cancer
- open label
- advanced non small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- tyrosine kinase
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- study protocol
- phase ii
- chronic myeloid leukemia